- Open Access
Activity of the novel BCR kinase inhibitor IQS019 in preclinical models of B-cell non-Hodgkin lymphoma
Journal of Hematology & Oncology volume 10, Article number: 80 (2017)
Pharmacological inhibition of B cell receptor (BCR) signaling has recently emerged as an effective approach in a wide range of B lymphoid neoplasms. However, despite promising clinical activity of the first Bruton’s kinase (Btk) and spleen tyrosine kinase (Syk) inhibitors, a small fraction of patients tend to develop progressive disease after initial response to these agents.
We evaluated the antitumor activity of IQS019, a new BCR kinase inhibitor with increased affinity for Btk, Syk, and Lck/Yes novel tyrosine kinase (Lyn), in a set of 34 B lymphoid cell lines and primary cultures, including samples with acquired resistance to the first-in-class Btk inhibitor ibrutinib. Safety and efficacy of the compound were then evaluated in two xenograft mouse models of B cell lymphoma.
IQS019 simultaneously engaged a rapid and dose-dependent de-phosphorylation of both constitutive and IgM-activated Syk, Lyn, and Btk, leading to impaired cell proliferation, reduced CXCL12-dependent cell migration, and induction of caspase-dependent apoptosis. Accordingly, B cell lymphoma-bearing mice receiving IQS019 presented a reduced tumor outgrowth characterized by a decreased mitotic index and a lower infiltration of malignant cells in the spleen, in tight correlation with downregulation of phospho-Syk, phospho-Lyn, and phospho-Btk. More interestingly, IQS019 showed improved efficacy in vitro and in vivo when compared to the first-in-class Btk inhibitor ibrutinib, and was active in cells with acquired resistance to this latest.
These results define IQS019 as a potential drug candidate for a variety of B lymphoid neoplasms, including cases with acquired resistance to current BCR-targeting therapies.
The B cell receptor (BCR) regulates multiple cellular processes which are critical for maintenance and survival of B cells, including proliferation, differentiation, and cell migration . Antigen engagement to BCR extracellular domain leads to phosphorylation and activation of immunoreceptor tyrosine-based activation motifs located in the cytoplasmic portion and other proteins downstream the receptor. Within BCR signalosome, the Lck/Yes novel tyrosine kinase (Lyn) recruits and phosphorylates the spleen tyrosine kinase (Syk), triggering a proliferation and survival cascade signaling that involves the phosphorylation and activation of Brutons’ tyrosine kinase (Btk), which subsequently phosphorylates phospholipase Cγ2 (PLCγ2), leading to calcium mobilization and activation of several downstream pathways, including MAP kinases, Akt and NF-κB . In addition to tonic, ligand-mediated BCR signaling, chronic BCR activation can occur in the absence of antigen engagement , leading to aberrant, constitutive BCR activation in several B cell non-Hodgkin lymphoma (B-NHL) subtypes, including diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL), follicular lymphoma (FL), and chronic lymphocytic leukemia (CLL) [4–7]. In these entities, BCR signaling represents an important pro-survival stimulus that may be stronger than in normal B cells, supporting the recent emergence of several BCR-targeting therapies . But despite the promising results obtained with the first kinase inhibitors, such as fostamatinib and ibrutinib, specific for the Src-family kinases Syk and Btk , the design of new compounds is warranted to improve treatment efficacy and to by-pass the resistance appearing in primarily responsive patients [9–11]. In this context, we recently described the synthesis of a new family of 4-aminopyrido[2,3-d]pyrimidines with kinase inhibitory property and antitumoral activity in B lymphoid cells. Compound 19 (thereafter referred as IQS019) was identified as the most effective and specific molecule, with growth inhibitory 50 (GI50) doses in the low micromolar range. Docking studies and biochemical assays further showed that the compound inhibited the active site of the BCR kinases Syk, Lyn, and Btk with higher efficacy than the reference kinase inhibitors [12, 13]. Here, using an extended panel of B-NHL cell lines and primary samples, we describe the full mechanism of action of this compound and report its remarkable antitumoral activity in vitro and in distinct B-NHL xenotransplant mouse models.
Cell lines and patients samples
Twenty-one cell lines from the different subtypes of B lymphoid neoplasm were used in this study (Table 1 and Additional file 1 Methods). All cell lines were routinely culture at 37 °C in a humidified atmosphere with 5% carbon dioxide in RPMI-1640, DMEM, or IMDM culture medium supplemented with 10–20% heat-inactivated fetal bovine serum (FBS), 2 mM glutamine, and 50 μg/ml penicillin-streptomycin (Thermo Fisher Scientific, Waltham, MA, USA). Primary tumor cells from 13 CLL patients (Additional file 1: Table S2) were used. Tumor cells were isolated, cryopreserved, and conserved within the Hematopathology collection of our institution (Hospital Clínic-IDIBAPS Biobank R121001-094), as previously described .
Kinase inhibition profiling
The kinase inhibition profile of IQS019 (0.1 and 10 μM) was evaluated at Proqinase (Freiburg, Germany) using a Kinase 400-Profiler Panel, according to previously described procedures . The residual activity (in %) for each compound well was calculated by using the following formula: Residual activity (%) = 100 x [(signal of compound–low control)/(high control–low control)].
Cell-based tyrosine kinase assay
In vitro inhibitory activity of IQS019 against BCR-related kinase was determined by Advanced Cell Dynamics (San Diego, CA, USA). Briefly, the Ba/F3 murine B lymphoid cell line was transfected with either a control vector or a vector containing the kinase domain of Btk, Syk, or Lyn, rending each cell line dependent upon activity of the recombinant kinase for survival. Cells were treated for 48 h with the indicated doses of IQS019 and cell viability was monitored via ATP concentration using CellTiter-Glo assay (Promega, Madison, WI, USA). IC50 values were determined using the GraphPad Prism software version 5.04 (San Diego, CA, USA)
Cell proliferation assay
Cells (4–6 x 105 cells/ml) were treated for the indicated times with IQS019 or ibrutinib (Selleck Chemicals, Munich, Germany) at doses ranging from 0.1 to 20 μM, and cell proliferation was determined by a modification of the MTT (3-(4,5-dimethylthiazolyl-2)-2,5-diphenyltetrazolium bromide) reduction method.
BCR stimulation and phospho-kinase detection
Cell lines (3–5 x 106 cells) and primary CLL samples (8–10 x 106 cells) were pretreated with 1 or 2.5 μM IQS019 for 90 min in FBS-free RPMI medium. Once starved, cells were incubated at 37 °C with 10 μg/ml of either anti-IgM (UPN-1, JVM-13, OCI-LY10 and primary CLL cells) or anti-IgG (DOHH-2) antibodies (Jackson Immunoresearch Laboratories, West Grove, PA, USA). Based on preliminary experiments showing a cell type-dependent variation in the optimal duration of the stimulation, cells were exposed to their respective anti-Ig for 2 min (UPN-1 and OCI-LY10 cells), 30 min (DOHH-2 and JVM-13 cells), and 15 min (CLL primary cells). Detection of phospho-Syk, phospho-lyn and phospho-Btk was carried out by western blot and flow cytometry, respectively, as detailed in Additional file 1 Methods.
Cell lines and CLL primary cells were exposed as indicated to IQS019, with or without BCR ligation, and CXCL12-induced migration was evaluated using 24-well chemotaxis chambers containing 8 μm (cell lines) or 5 μm (primary cells) pore size inserts (Corning Life Science, Tewksbury, MA, USA), as previously described . To quantify CXCR4-dependent F-actin polymerization, cells (300.000–500.000) treated as above were fixed on poly-L-lysine–coated glass coverslips with 4% paraformaldehyde, washed in PBS, permeabilized for 10 min with a solution containing 0.1% saponin (in PBS), followed by a 30 min incubation with 50 μg/ml phalloidin-TRITC (Sigma-Aldrich). Then, coverslips were washed three times with saponin 0.03%, mounted on glass slides with DAPI-containing Fluoroshield mounting medium (Sigma-Aldrich), and visualized on a Nikon H5505 microscope by means of a 60X NA oil objective (Nikon, Amsterdam, Netherlands) with the use of Isis Imaging System v5.3 software (MetaSystems GmbH, Heidelberg, Germany).
Xenograft mouse models and immunohistochemical studies
For MCL xenotransplant model, CB17-SCID female mice (Janvier Labs, Le Genest-Saint-Isle, France) were inoculated subcutaneously with UPN-1 cells as previously described .Tumor-bearing mice were randomly assigned into equivalent cohorts and received a daily dose of 2 mg/kg, 10 mg/kg (i.p.), or 25 mg/kg (p.o.) IQS019-2MeSO3H or ibrutinib, or equal volume of vehicle, for 15 days, in a five/two (on/off) schedule. Animals were sacrificed and tumor samples were processed and stained for phospho-Histone H3 and cleaved caspase-3 as previously described . Detection of phospho-Syk, phospho-Lyn and phospho-Btk was carried out from OCT tumor section as explained in Additional file 1 Methods. For systemic FL model, 12 SCID mice were intravenously inoculated via tail vein with 1.5 x 107 DOHH-2 cells per mouse. One week later, animals were randomly assigned into two equivalent cohorts and treated intraperitoneally with 2 mg/kg IQS019-2MeSO3H or vehicle, as before. Mice were then sacrificed and immunodetection of phospho-BCR kinases was performed as detailed in Additional file 1 Methods.
Unless otherwise specified, the data are depicted as the mean ± SD of three independent experiments. Unpaired and paired T-tests were used to obtain the statistical analysis using Graph Pad Prism software 4.0. Results were considered statistically significant when p < 0.05 (*, **p < 0.01, ***p < 0.001).
Antitumor effect of the 4-aminopyrido[2,3-d]pyrimidine IQS019 in B lymphoid cell lines and primary samples
To assess the selectivity of the kinase inhibitor IQS019 (Fig. 1a and ref ), we first evaluated its inhibitory property against a panel of 400 kinases, including 70 disease-relevant protein kinase mutants and 13 lipid kinases, covering about 60% of the human kinome. We found the compound to be preferentially active against tyrosine kinase (TK) and tyrosine kinase-like (TKL) families, reaching a mean residual kinase activity of 28% at a 10 μM dose, while this activity remained above 70% in all the other kinase subgroups (Fig. 1b, *** p < 0.001 and Additional file 1: Figure S1). Of special interest, in a set of 17 TK/TKLs, the compound was able to inhibit at least 20% of the kinase activity at the lowest dose (0.1 μM) and to achieve an almost complete kinase inactivation at the 10 μM concentration. These kinases corresponded to leucocyte-, BCR-, or T-cell receptor (TCR)-related kinases (Lyn, Blk, Lck, Src, Frk, Csk, Hck, Fyn, Btk, Syk), the member of the Tec family of non-receptor tyrosine kinases, Bmx, and other receptor tyrosine kinases with lower relevance in B-NHL, such as Ddr2, Egfr, EphA, Erbb, Fgr and Braf (Additional file 1: Table S1). Among these potential targets, a radiometric kinase activity study further showed that IQS019 had an IC50 in the low micromolar range for the BCR kinases Lyn (0.15 μM), Syk (1.6 μM) and Btk (2.1 μM), corresponding to those kinases able to bind the compound in their active site . Accordingly, ectopic expression of each individual kinase in B lymphoid cells rendered them dependent of these kinases for their survival and increased cell sensitivity to IQS019. Indeed, while the calculated IC50 of the compound was 5.4 μM in parental Ba/F3 cells, this value decreased to 2.2, 1.4, and 2.2 μM in Btk-, Lyn-, or Syk-overexpressing cells, respectively (Fig. 1c). Thus, these results confirm that IQS019 is a potent tyrosine kinase inhibitor, with the unique ability to bind and to simultaneously inhibit the three BCR kinases Lyn, Syk, and Btk.
We further assessed the activity of the compound in vitro using a panel of 21 B-NHL cell lines representative of the CLL, MCL, FL and DLBCL subtypes (Table 1). We show that a 5 μM dose of the compound decreased cell proliferation in all the cell lines (range: 29–100%), being MCL and FL cells significantly more sensitive to the compound (mean cytotoxicity at 48 h: 67.2 ± 15%) than CLL cells and DLBCL cells of either activated B-cell (ABC) or germinal centre B-cell (GCB) subtype (mean cytotoxicity at 48 h: 42 ± 9%) (p = 0.0002). Based on these results, a set of 13 CLL primary cultures were exposed for 24 h to increasing doses of IQS019 and cell viability was measured by MTT assay. Although a high variability was observed among cases, the viability decreased in a dose-dependent manner in all the samples treated with the compound (Fig. 1d). The calculated IC50 was 6.1 μM in this set of samples, corresponding to the upper range of the values found in the cell lines. Similar responses were observed in FL and MCL primary cultures (data not shown). Of note, no association could be established between sensitivity to IQS019 and common cytogenetic alterations, TP53 mutation and/or deletion, or IGHV mutational status (Table 1, Additional file 1: Table S2 and Figure S2a). Of interest, a 24 h treatment with a 5 μM dose of the compound induced about 35% apoptosis increase in the representative cell lines UPN-1 and DOHH-2 (Additional file 1: Figure S2b). In CLL and primary cultures (n = 6) the average cell death induction reached 26% (range: 9.5–51.5%), as shown in the representative cases, CLL n.2 and CLL n.10 (Additional file 1: Figure S2b and data not shown). This phenomenon was completely abrogated in the presence of the pan-caspase inhibitor Q-VD-OPh. In parallel, the analysis of phospho-histone H3 levels as a surrogate of mitotic progression indicated a notable decrease of this marker in five out of six primary CLL cases treated with the compound (Additional file 1: Figure S2c). Thus, altogether these results demonstrate that IQS019 antitumor activity in B lymphoid cells involved both a blockade in cell proliferation and the induction of a caspase-dependent cell death.
IQS019 antagonizes constitutive and antigen-mediated BCR signaling
Based on the above results, we analyzed the effect of IQS019 on the phosphorylation status of Syk, Lyn and Btk in four cell lines representative of MCL (UPN-1), FL (DOHH-2), CLL (JVM-13), and DLBCL (OCI-LY10) subtypes. Cells were incubated for 6 h with increasing concentrations of IQS019 and phosphorylation levels of Syk and Lyn at their respective Tyr352 and Tyr396 residues, were evaluated by Western blot, while Btk phosphorylation at Tyr223 residue was analyzed by flow cytometry. As observed in Fig. 2a, IQS019 treatment led to a dose-dependent dephosphorylation of Syk and Lyn in the four cell lines tested. Consistent with the cytotoxicity of the compound (Table 1), a complete dephosphorylation of the two kinases was observed in UPN-1 and DOHH-2, while a slight, persistent phosphorylation of both Syk and Lyn was detected in OCI-LY10 and JVM-13 cells (Fig. 2a). Regarding Btk phosphorylation, flow cytometry analysis showed a 30% (UPN-1 and OCI-LY10) and a 60% (DOHH-2 and JVM-13) decrease in the relative mean fluorescence intensity ratio (r) of phospho-Btk signal in cells exposed to a 5 μM dose of the compound (Fig. 2b).
In a second step, the four previous cell lines and two representative primary CLL cases were BCR-stimulated with their corresponding anti-Ig in the presence of increasing concentrations of IQS019, and phospho-Syk, phospho-Lyn and phospho-Btk levels were analyzed as above. As shown in Fig. 3a, BCR ligation induced an increase in the phosphorylation levels of Syk and Lyn in all the samples tested, that was hampered by IQS019 in a dose-dependent manner. Remarkably, a dose of IQS019 as low as 1 μM was sufficient to completely counteract the anti-IgM-mediated activation of Syk and Lyn in the highly IgM-responsive (unmutated IGHV) CLL sample showing the greatest efficacy of the stimulation (CLL#10, Fig. 3a). Similarly, IQS019 efficiently counteracted Ig-induced Btk phosphorylation in cell lines, as shown by a 30 to 70% reduction in relative phospho-Btk levels (Fig. 3b). In CLL primary cells, for all but 1 cases out of the 6 examined, IQS019 achieved a 30% reduction in phospho-Btk levels (p = 0.0005), as shown in the representative CLL no.10 (Fig. 3b and data not shown). Of note, in the representative cell line UPN-1, Syk-dependent phosphorylation of Btk at Tyr551 was negligible upon BCR triggering and remained unaffected in the presence of IQS019 (data not shown), suggesting that IQS019-mediated inhibition of Btk requires a direct interaction of the compound with the kinase, rather than an indirect, Syk-mediated signal transduction. Altogether, these results suggest than IQS019 counteracts both constitutive and antigen-induced BCR signaling in B lymphoid cell lines and primary cells.
IQS019 inhibits CXCL12-mediated migration of malignant B cells
Migration of neoplastic B cells has been shown to be heavily affected upon exposure to drugs targeting the BCR-associated kinases, as these latest tightly regulate the re-organization of the cytoskeleton required for cell chemotaxis . Thus, we evaluated the effect of IQS019 on the migratory capacity of malignant B cells, using a CXCL12-dependent chemotaxis assay with 3 cell lines harboring detectable levels of CXCR4 (Additional file 1: Figure S3) and in a set of seven CLL primary samples, either untreated or pre-treated with IQS019 or with the standard CXCR4 antagonist AMD3100. The migration induced by recombinant CXCL12 in MCL, FL and DLBCL cell lines was significantly inhibited by the compound at all the doses tested (Fig. 4a). The statistical significance of this effect was higher at the 2.5 μM than at the 1 μM dose in DOHH-2 and OCI-LY10 cells, while an almost complete inhibition of cell migration was achieved in UPN-1 cells at the lowest dose. In the case of CLL primary cells, since the stimulation of BCR has been shown to facilitate CXCL12-mediated migration , we evaluated the activity of IQS019 after BCR crosslinking. As shown in Fig. 4b, c, IQS019 significantly overcame IgM-activated, CXCL12-dependent chemotaxis in all the primary samples tested, either at the 1 μM dose (mean inhibition: 51.5%; range: 23.9–85.5%; p = 0.0013) or at the 2.5 μM dose (mean inhibition: 82.9%; range: 63.4–97.6%; p < 0.0001), when compared to untreated control cells. Accordingly, the mean fraction of cells with detectable F-actin polymerization shifted from 13.8% in control cells to 75.1% after CXCL12 stimulation, and was lowered down to 25.9% in the presence of IQS019 (Fig. 4d, *** p = 0.0003). Of special interest, when comparing with AMD3100, IQS019 showed similar, or even superior anti-migratory activity (Fig. 4a, b and c). These results indicate that IQS019-mediated inhibition of BCR upstream kinases may interfere with B cell chemotaxis and tumor cell dissemination.
IQS019 is safe and impairs tumor outgrowth and malignant B cell homing to spleen in vivo
In order to validate the activity of IQS019 in vivo, we first synthesized the salt form of the compound, thereafter labeled as IQS019-2MeSO3H, and evaluated its single-dose toxicity over 14 days after intravenous administration in healthy immunodeficient (SCID) mice (details in Additional file 1 Methods). As the maximum tolerated dose was not reached, 2 and 10 mg/kg doses were selected for further in vivo experiments. We then developed two different, complementary xenotransplant animal models of the two entities showing increased sensitivity to the compound in vitro, i.e., MCL and FL. Heterotopic MCL tumors were generated in SCID mice subcutaneously inoculated with UPN-1 cells, while a systemic (i.e., characterized by homing of tumor B cells from peripheral blood to spleen) FL tumor model was obtained by intravenous injection of DOHH-2 cells in SCID mice. As shown in Fig. 5a, after two weeks of treatment, mice bearing MCL tumors and dosed with IQS019-2MeSO3H showed a 63% reduction in tumor volume, when compared to the vehicle group (*p < 0.05). There was not subsequent improvement of the anti-tumor activity of the compound between the 2 mg/kg and the 10 mg/kg dosing, suggesting that optimal activity was reached at the lowest dose. Consistently, tumor metabolism was similarly decreased in both treatment groups, as glucose uptake fell to 50–52% in tumors from all IQS019-2MeSO3H-exposed animals, irrespective of the dose (Fig. 5b). This effect was closely related to the inhibition of the three BCR-related kinases Syk, Lyn, and Btk, as shown by a complete reduction of their phosphorylated forms in the drug-treated specimens, when compared to the control group (Fig. 5c). Immunohistochemical analysis of representative tumor sections further revealed that IQS019 therapy efficiently reduced the mitotic index and induced apoptosis in UPN-1-derived tumors, as shown by a decreased labeling of phospho-histone H3 and an intracellular increase in the activated form of caspase-3 (Fig. 5c).
In the systemic DOHH-2 mouse model, mice dosing was initiated at day 7 post-inoculation, with a 2 mg/kg IQS019-2MeSO3H regimen, daily, for 15 days. Once inoculated, FL cells rapidly migrate to the spleen . Therefore, at the end of the procedure, entire spleens were processed, and the presence of malignant B cells was evaluated by labeling with anti-human CD45 antibody and tumor cell recounting on a flow cytometer. IQS019-2MeSO3H treatment induced a 52% reduction in tumor cell infiltration into the spleen, when compared to vehicle group (Fig. 5d, * p = 0.01). Accordingly, the r fluorescence values of phospho-Syk, phospho-Btk, and phospho-Lyn, decreased by 83, 57, and 33% in tumors B cells purified from IQS019-treated animals (Fig. 5e). Altogether, these results demonstrate that IQS019 is safe and exhibits in vivo efficacy against MCL and FL tumor burden, involving the inhibition of BCR signaling and the blockade of tumor cell homing to lymphoid compartment.
IQS019 shows superior anti-tumor activity than ibrutinib in vitro and in vivo
We previously reported that IQS019 presented an increased anti-proliferative activity in vitro when compared to ibrutinib, in a single MCL cell line and at a single time point . To confirm this preliminary experiment, we compared by MTT assay the anti-proliferative effect of IQS019 and ibrutinib at 24, 48, and 72 h, using doses ranging from 0.5 to 10 μM, in a panel of eight cell lines that included the ibrutinib-sensitive MINO, REC-1, UPN-1, DOHH-2, and WSU-NHL and the ibrutinib-resistant Z-138, GRANTA-519, and JVM-2 cells. Figure 6a shows that the mean IC50 of ibrutinib remained significantly high (i.e., > 10 μM) in this set of cell lines, even after a 72-h drug exposure, mainly due to the high values observed in the resistant cell lines (152.4 μM for Z-138, 22.1 μM for GRANTA-519 and 77.4 μM for JVM-2). In contrast, IQS09-mediated proliferation blockade was almost completely reached in all the cell lines after only 24 hours, with a mean IC50 of 6.7 μM (range: 2.7–8.7 μM), which decreased down to 4.1 μM (range: 2.2–11.7 μM) and 3.3 μM (range: 2.2-5.1 μM) at 48 h and 72 h, respectively. Of particular interest, after 72 h these IC50 values were much lower in Z-138 (4.5 μM), GRANTA-519 (5.1 μM), and JVM-2 cells (4.1 μM) than observed after ibrutinib treatment. Accordingly, while a short exposure to ibrutinib only marginally affected CXCL12-dependent cell migration in the UPN-1 cell line, this process was blocked up to 39% in cells cultured with IQS019 (Fig. 6b). To validate these observations in in vivo settings, MCL tumor-bearing mice were treated with a standard 25 mg/kg dose of ibrutinib , the equivalent dose of IQS019-2MeSO3H, or vehicle. While ibrutinib allowed to a significant 25.1% reduction in tumor growth after 2 weeks of treatment (* p = 0.049), IQS019-2MeSO3H showed superior activity, as it could inhibit the tumor outgrowth up to 42% when compared to vehicle group (Fig. 6c, ** p = 0.006, * p = 0.048). At the pharmacokinetic level, while both compounds presented similar half-life and Cmax values in mice after a single oral administration, the total drug exposure over time was considerably improved in the case of IQS019-2MeSO3H, as shown by a 12 fold increase in the AUC value. Consequently, the global bioavailability dropped from 2 to 4% in the case of ibrutinib, to about 70% in the case of IQS019-2MeSO3H (Additional file 1: Figure S4b and Table S3), thus suggesting that a better PK profile may account for the improved activity of IQS019 vs ibrutinib in vivo.
To unravel at the molecular level the mechanisms underlying this superior activity of IQS019 over the Btk inhibitor, we established an ibrutinib-resistant cell line designated UPN-IbruR, derived from the parental UPN-1 by repeated drug selection (Additional file 1 Methods). When compared with the parental cell line, UPN-IbruR presented approximately a 10-fold increase in the ibrutinib IC50 after 72 h of treatment (24.6 vs 2.4 μM for parental cells), with negligible difference in IQS019 IC50 (5.6 vs 2.3 μM for parental cells) (Additional file 1: Figure S5a).The ibrutinib resistance phenotype of UPN-IbruR cells was not associated to mutations in BTK or PLCG2 genes, which both harbored a wild type sequence (Additional file 1: Figure S5b), but may rather be associated to the activation of non-canonical NF-κB pathway, as suggested by the overexpression of p52 (Additional file 1: Figure S5c). While a similar dose-dependent decrease in phospho-Lyn and phospho-Btk levels was found in IQS019- and in ibrutinib-treated UPN-1 cells, the expression of phospho-Syk was almost completely lost only in cells exposed to 1 μM IQS019 (Fig. 6d,e). In sharp contrast, in UPN-IbruR cells, the Btk inhibitor failed to modulate the phosphorylation of the three kinases, while IQS019 showed significant inhibitory activity of phospho-Syk and phospho-Lyn at a dose as low as 1 μM (Fig. 6d). However, the compound was unable to downregulate phospho-Btk (Fig. 6e), suggesting that in ibrutinib-resistant cells, the capacity of IQS019 to inhibit Syk and Lyn may allow the compound to maintain a significant antitumoral activity independent of the expression of a non-druggable form of Btk. Altogether, these results point out a significant superior antitumoral activity of pleiotropic BCR kinase targeting by IQS019 over the sole inhibition of Btk, in in vitro and in vivo models of B-NHL.
BCR has recently emerged as a central oncogenic pathway that promotes growth and survival in various lymphoma subtypes . Constitutive activation of the three BCR-related kinases Syk, Lyn, and Btk have been well documented in CLL [18–20], MCL [21, 22], and FL  cells, while chronic BCR signaling has been reported in the ABC subtype of DLBCL . Consistently, BCR kinase inhibitors constitute promising therapeutic strategies in these different entities. Among these novel agents, the first-in-class Btk inhibitor ibrutinib has achieved high response rates (43–71%) in relapsed/refractory CLL, MCL and ABC-DLBCL patients, while its activity was less pronounced in FL patients (37% overall response rate) [24–27]. A small fraction of patients develop progressive disease after initial response to this agent [25, 27], in relation with the acquisition of mutations at the ibrutinib binding site (C481S) of Btk, or in the PLCγ2 gene [9–11]. Resistance to ibrutinib may also involve a lower dependency of malignant B cells toward Btk itself, than other downstream components of the pathway, like the Syk/Lyn-dependent kinase Erk . Accordingly, the Syk inhibitor fostamatinib and the Src inhibitor dasatinib have also shown efficacy in relapsed/refractory B-NHL [29, 30].
Following these observations, and in an effort to improve the therapeutic modulation of BCR signaling, we previously screened a library of compounds derived from pyrido[2,3-d]pyrimidines, for their capacity to bind to the active sites of Btk, Syk and/or Lyn . We identified IQS019 (compound 19) as a unique molecule with affinity for the three BCR kinases . In the present work, we confirm the inhibitory property of the compound against Btk, Syk and Lyn, as well as its selective antitumoral effect in B lymphoid cells, especially in MCL and FL cell lines, and independently of the response to ibrutinib. Our results suggest that IQS019 can counteract both chronic and tonic BCR signaling, as it shows similar antiproliferative activity in DLBCL cell lines from both the GCB and ABC subtype, which are respectively dependent for their survival on tonic (Syk/PI3K-mediated) and chronic (Syk/Btk-mediated) BCR signaling [8, 32–34]. This property might confer to IQS019 a greater activity than ibrutinib, which is preferentially active against tumors that rely on chronic active BCR signaling . Beside Btk, the direct inhibitory activity of IQS019 towards Syk and/or Lyn phosphorylation may also explain the capacity of the compound to activate apoptosis in vitro and in vivo, as pharmacological inhibition of Syk, has been reported to elicit the apoptotic cascade in preclinical models of DLBCL and CLL [35, 36]. Also, probably thanks to its apoptogenic property and specificity, IQS019 salt is found to be significantly active and safe at a dose of 2 mg/kg/day, which is much lower than the reported active concentrations of fostamatinib, dasatinib or ibrutinib in mouse models of lymphoid neoplasms [37–39], thus predicting a probable low incidence of secondary adverse effects of the compound.
Another downstream event regulated by Btk, Syk, and Lyn is the chemokine-mediated B cell migration, a process essential to tumor B cell survival . We show that IQS019 is able to impair in vitro cell migration towards CXCL12 in cell lines and primary samples, in both basal and anti-Ig-stimulated cultures. This property may be responsible, at least in part, for the reduced infiltration of tumor cell observed in FL-bearing mice dosed with the compound. Beside this effect, IQS019-mediated inhibition of Syk, Lyn, and Btk may further impair tumor maintenance and B cell homeostasis in vivo, which are largely dependent on the coordinated activity of the three kinases .
In summary, we describe IQS019 as a new and unique BCR kinase inhibitor able to counteract both constitutive and ligand-dependent activation of the BCR pathway in in vitro and in vivo models of B lymphoid neoplasms. Thanks to the unique capacity of the compound to inhibit the three upstream BCR kinases Lyn, Syk, and Btk, this study may offer a glimpse into possible application for the treatment of the most prevalent subtypes of B-NHL, including those low responders to current BCR kinase inhibitors.
A, G, and C protein kinase group
B cell receptor
B-cell non-Hodgkin lymphoma
Ca2+/calmodulin-dependent protein kinase
Chronic lymphocytic leukemia
Cyclin-dependent (CDKs), mitogen-activated, glycogen synthase and CDK-like protein kinase group
Diffuse large B-cell lymphoma
Fetal bovine serum
Germinal centre B-cell
- GI50 :
Growth inhibitory 50
Lck/Yes novel tyrosine kinase
Mantle cell lymphoma
Mitogen-activated protein kinase cascade component
Spleen tyrosine kinase
Avalos AM, Meyer-Wentrup F, Ploegh HL. B-cell receptor signaling in lymphoid malignancies and autoimmunity. Adv Immunol. 2014;123:1–49.
Pierce SK, Liu W. The tipping points in the initiation of B cell signalling: how small changes make big differences. Nat Rev Immunol. 2010;10(11):767–77.
Monroe JG. ITAM-mediated tonic signalling through pre-BCR and BCR complexes. Nat Rev Immunol. 2006;6(4):283–94.
Baran-Marszak F, Boukhiar M, Harel S, Laguillier C, Roger C, Gressin R, Martin A, Fagard R, Varin-Blank N, Ajchenbaum-Cymbalista F, Ledoux D. Constitutive and B-cell receptor-induced activation of STAT3 are important signaling pathways targeted by bortezomib in leukemic mantle cell lymphoma. Haematologica. 2010;95(11):1865–72.
Davis RE, Ngo VN, Lenz G, Tolar P, Young RM, Romesser PB, Kohlhammer H, Lamy L, Zhao H, Yang Y, Xu W, Shaffer AL, Wright G, Xiao W, Powell J, Jiang JK, Thomas CJ, Rosenwald A, Ott G, Muller-Hermelink HK, Gascoyne RD, Connors JM, Johnson NA, Rimsza LM, Campo E, Jaffe ES, Wilson WH, Delabie J, Smeland EB, Fisher RI, Braziel RM, Tubbs RR, Cook JR, Weisenburger DD, Chan WC, Pierce SK, Staudt LM. Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. Nature. 2010;463(7277):88–92.
Duhren-von MM, Ubelhart R, Schneider D, Wossning T, Bach MP, Buchner M, Hofmann D, Surova E, Follo M, Kohler F, Wardemann H, Zirlik K, Veelken H, Jumaa H. Chronic lymphocytic leukaemia is driven by antigen-independent cell-autonomous signalling. Nature. 2012;489(7415):309–12.
Sachen KL, Strohman MJ, Singletary J, Alizadeh AA, Kattah NH, Lossos C, Mellins ED, Levy S, Levy R. Self-antigen recognition by follicular lymphoma B-cell receptors. Blood. 2012;120(20):4182–90.
Young RM, Staudt LM. Targeting pathological B cell receptor signalling in lymphoid malignancies. Nat Rev Drug Discov. 2013;12(3):229–43.
Cheng S, Guo A, Lu P, Ma J, Coleman M, Wang YL. Functional Characterization of BTKC481S mutation that confers ibrutinib resistance: Exploration of alternative kinase inhibitors. Leukemia. 2015;29(4):895–900.
Chiron D, Di Liberto M, Martin P, Huang X, Sharman J, Blecua P, Mathew S, Vijay P, Eng K, Ali S, Johnson A, Chang B, Ely S, Elemento O, Mason Christopher E, Leonard John P, Chen-Kiang S. Cell-cycle reprogramming for PI3K inhibition overrides a relapse-specific C481S BTK mutation revealed by longitudinal functional genomics in mantle cell lymphoma. Cancer Discovery. 2014;4(9):1022–35.
Woyach Jennifer A, Furman Richard R, Liu Ta M, Ozer Hatice G, Zapatka M, Ruppert Amy S, Xue L, Li Daniel H-H, Steggerda Susanne M, Versele M, Dave Sandeep S, Zhang J, Yilmaz Ayse S, Jaglowski Samantha M, Blum Kristie A, Lozanski A, Lozanski G, James Danelle F, Barrientos Jacqueline C, Lichter P, Stilgenbauer S, Buggy Joseph J, Chang Betty Y, Johnson Amy J, Byrd John C. Resistance mechanisms for the Bruton’s tyrosine kinase inhibitor ibrutinib. N Engl J Med. 2014;370(24):2286–94.
Borrell JI, Teixido J, Puig de la Bellacasa R, Colomer D, Roue G, and Perez-Galan P. 4-Amino-6-(2,6-dichlorophenyl)-2-(phenylamino)pyrido[2,3-d]pyrimidin-7(8H)-one derivatives, synthesis and uses thereof. 2013;EP 13382225. https://www.google.com/patents/EP2813504A1?cl=en&hl=es.
Puig de la Bellacasa R, Roue G, Balsas P, Perez-Galan P, Teixido J, Colomer D, Borrell JI. 4-Amino-2-arylamino-6-(2,6-dichlorophenyl)-pyrido[2,3-d]pyrimidin-7-(8H)-ones as BCR kinase inhibitors for B lymphoid malignancies. Eur J Med Chem. 2014;86C:664–75.
Moros A, Rodriguez V, Saborit-Villarroya I, Montraveta A, Balsas P, Sandy P, Martinez A, Wiestner A, Normant E, Campo E, Perez-Galan P, Colomer D, Roue G. Synergistic antitumor activity of lenalidomide with the BET bromodomain inhibitor CPI203 in bortezomib-resistant mantle cell lymphoma. Leukemia. 2014;27(10):2049–59.
Lopez-Guerra M, Xargay-Torrent S, Perez-Galan P, Saborit-Villarroya I, Rosich L, Villamor N, Aymerich M, Roue G, Campo E, Montserrat E, Colomer D. Sorafenib targets BCR kinases and blocks migratory and microenvironmental survival signals in CLL cells. Leukemia. 2012;26(6):1429–32.
Smith MR, Joshi I, Jin F, Obasaju C. Enhanced efficacy of gemcitabine in combination with anti-CD20 monoclonal antibody against CD20+ non-Hodgkin’s lymphoma cell lines in vitro and in scid mice. BMC Cancer. 2005;5:103.
Ponader S, Chen SS, Buggy JJ, Balakrishnan K, Gandhi V, Wierda WG, Keating MJ, O’Brien S, Chiorazzi N, Burger JA. The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo. Blood. 2012;119(5):1182–9.
Contri A, Brunati AM, Trentin L, Cabrelle A, Miorin M, Cesaro L, Pinna LA, Zambello R, Semenzato G, Donella-Deana A. Chronic lymphocytic leukemia B cells contain anomalous Lyn tyrosine kinase, a putative contribution to defective apoptosis. J Clin Invest. 2005;115(2):369–78.
Buchner M, Fuchs S, Prinz G, Pfeifer D, Bartholome K, Burger M, Chevalier N, Vallat L, Timmer J, Gribben JG, Jumaa H, Veelken H, Dierks C, Zirlik K. Spleen tyrosine kinase is overexpressed and represents a potential therapeutic target in chronic lymphocytic leukemia. Cancer Res. 2009;69(13):5424–32.
Herman SE, Gordon AL, Hertlein E, Ramanunni A, Zhang X, Jaglowski S, Flynn J, Jones J, Blum KA, Buggy JJ, Hamdy A, Johnson AJ, Byrd JC. Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765. Blood. 2011;117(23):6287–96.
Rinaldi A, Kwee I, Taborelli M, Largo C, Uccella S, Martin V, Poretti G, Gaidano G, Calabrese G, Martinelli G, Baldini L, Pruneri G, Capella C, Zucca E, Cotter FE, Cigudosa JC, Catapano CV, Tibiletti MG, Bertoni F. Genomic and expression profiling identifies the B-cell associated tyrosine kinase Syk as a possible therapeutic target in mantle cell lymphoma. Br J Haematol. 2006;132(3):303–16.
Pighi C, Gu TL, Dalai I, Barbi S, Parolini C, Bertolaso A, Pedron S, Parisi A, Ren J, Cecconi D, Chilosi M, Menestrina F, Zamo A. Phospho-proteomic analysis of mantle cell lymphoma cells suggests a pro-survival role of B-cell receptor signaling. Cell Oncol (Dordr). 2011;34(2):141–53.
Leseux L, Hamdi SM, Al Saati T, Capilla F, Recher C, Laurent G, Bezombes C. Syk-dependent mTOR activation in follicular lymphoma cells. Blood. 2006;108(13):4156–62.
Advani RH, Buggy JJ, Sharman JP, Smith SM, Boyd TE, Grant B, Kolibaba KS, Furman RR, Rodriguez S, Chang BY, Sukbuntherng J, Izumi R, Hamdy A, Hedrick E, Fowler NH. Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies. J Clin Oncol. 2013;31(1):88–94.
Byrd JC, Furman RR, Coutre SE, Flinn IW, Burger JA, Blum KA, Grant B, Sharman JP, Coleman M, Wierda WG, Jones JA, Zhao W, Heerema NA, Johnson AJ, Sukbuntherng J, Chang BY, Clow F, Hedrick E, Buggy JJ, James DF, O’Brien S. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med. 2013;369(1):32–42.
Cameron F, Sanford M. Ibrutinib: first global approval. Drugs. 2014;74(2):263–71.
Wang ML, Rule S, Martin P, Goy A, Auer R, Kahl BS, Jurczak W, Advani RH, Romaguera JE, Williams ME, Barrientos JC, Chmielowska E, Radford J, Stilgenbauer S, Dreyling M, Jedrzejczak WW, Johnson P, Spurgeon SE, Li L, Zhang L, Newberry K, Ou Z, Cheng N, Fang B, McGreivy J, Clow F, Buggy JJ, Chang BY, Beaupre DM, Kunkel LA, Blum KA. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med. 2013;369(6):507–16.
Ma J, Lu P, Guo A, Cheng S, Zong H, Martin P, Coleman M, Lynn WY. Characterization of ibrutinib-sensitive and -resistant mantle lymphoma cells. Br J Haematol. 2014;166(6):849–61.
Amrein PC, Attar EC, Takvorian T, Hochberg EP, Ballen KK, Leahy KM, Fisher DC, Lacasce AS, Jacobsen ED, Armand P, Hasserjian RP, Werner L, Neuberg D, Brown JR. Phase II study of dasatinib in relapsed or refractory chronic lymphocytic leukemia. Clin Cancer Res. 2011;17(9):2977–86.
Friedberg JW, Sharman J, Sweetenham J, Johnston PB, Vose JM, Lacasce A, Schaefer-Cutillo J, De Vos S, Sinha R, Leonard JP, Cripe LD, Gregory SA, Sterba MP, Lowe AM, Levy R, Shipp MA. Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia. Blood. 2010;115(13):2578–85.
Wu K, Ai J, Liu Q, Chen T, Zhao A, Peng X, Wang Y, Ji Y, Yao Q, Xu Y, Geng M, Zhang A. Multisubstituted quinoxalines and pyrido[2,3-d]pyrimidines: synthesis and SAR study as tyrosine kinase c-Met inhibitors. Bioorg Med Chem Lett. 2012;22(20):6368–72.
Davids Matthew S, Brown Jennifer R. Ibrutinib: a first in class covalent inhibitor of Bruton’s tyrosine kinase. Future Oncol. 2014;10(6):957–67.
Seda Vaclav and Mraz Marek. B-cell receptor signalling and its crosstalk with other pathways in normal and malignant cells. Eur J Haematol. 2014;n/a-n/a.
Wilson WH, Gerecitano JF, Goy A. The Bruton’s tyrosine kinase (BTK) inhibitor, ibrutinib (PCI-32765), has preferential activity in the ABC subtype of relapsed/refractory de novo diffuse large B-cell lymphoma (DLBCL): Interim results of a multicenter, open-label, Phase 2 study. ASH Annual Meeting Abstracts. 2012;2012:686.
Buchner M, Baer C, Prinz G, Dierks C, Burger M, Zenz T, Stilgenbauer S, Jumaa H, Veelken H, Zirlik K. Spleen tyrosine kinase inhibition prevents chemokine- and integrin-mediated stromal protective effects in chronic lymphocytic leukemia. Blood. 2010;115(22):4497–506.
Chen L, Monti S, Juszczynski P, Ouyang J, Chapuy B, Neuberg D, Doench JG, Bogusz AM, Habermann TM, Dogan A, Witzig TE, Kutok JL, Rodig SJ, Golub T, Shipp MA. SYK inhibition modulates distinct PI3K/AKT- dependent survival pathways and cholesterol biosynthesis in diffuse large B cell lymphomas. Cancer Cell. 2013;23(6):826–38.
Dargart JL, Fish K, Gordon LI, Longnecker R, Cen O. Dasatinib therapy results in decreased B cell proliferation, splenomegaly, and tumor growth in a murine model of lymphoma expressing Myc and Epstein-Barr virus LMP2A. Antiviral Res. 2012;95(1):49–56.
Fruchon S, Kheirallah S, Al Saati T, Ysebaert L, Laurent C, Leseux L, Fournie JJ, Laurent G, Bezombes C. Involvement of the Syk-mTOR pathway in follicular lymphoma cell invasion and angiogenesis. Leukemia. 2012;26(4):795–805.
Herman SE, Sun X, McAuley EM, Hsieh MM, Pittaluga S, Raffeld M, Liu D, Keyvanfar K, Chapman CM, Chen J, Buggy JJ, Aue G, Tisdale JF, Perez-Galan P, Wiestner A. Modeling tumor-host interactions of chronic lymphocytic leukemia in xenografted mice to study tumor biology and evaluate targeted therapy. Leukemia. 2013;27(12):2311–21.
Quiroga MP, Balakrishnan K, Kurtova AV, Sivina M, Keating MJ, Wierda WG, Gandhi V, Burger JA. B-cell antigen receptor signaling enhances chronic lymphocytic leukemia cell migration and survival: specific targeting with a novel spleen tyrosine kinase inhibitor, R406. Blood. 2009;114(5):1029–37.
Wiestner A. Emerging role of kinase-targeted strategies in chronic lymphocytic leukemia. Hematol Am Soc Hematol Educ Program. 2012;2012:88–96.
The authors gratefully acknowledge Pangaea Biotech for its involvement and support to the project and thank Sandra Cabezas for technical assistance.
This work was financially supported by Fondo de Investigación Sanitaria PI12/01847 and PI15/00102 (to G.R.), PI0110094 (to A.M.), European Regional Development Fund (ERDF) “Una manera de hacer Europa”, Ministerio de Ciencia e Innovación, SAF12/31242 (to D.C.), SAF11/29326 (to P.P.-G.), SAF2010-C21617-C02 (to JI.B.), Redes Temáticas de Investigación Cooperativa de Cáncer from the Instituto de Salud Carlos III (ISCIII) RD12/0036/0004 (to D.C.) and RD12/0036/0039 (to E.C.) and Generalitat de Catalunya 2014SGR346 (to D.C.) and 2014SGR795 (to E.C.). A.E.-A. and A.M.-C. were recipients of predoctoral fellowships from Ministerio de Ciencia e Innovación and A.M. hold an IDIBAPS intramural predoctoral fellowship. R.P. was supported by a grant within the Talent empresa 2009 program (2009 TEM 00128) of the Generalitat de Catalunya. AC-J holds a postdoctoral fellowship from Catalonian Agency for Management of University and Research Grants (AGAUR, Beatriu de Pinos program). This work was carried out at the Esther Koplowitz Center, Barcelona, under the CERCA Program (Generalitat de Catalunya).
Availability of data and materials
All relevant data and materials within this work are made available in this manuscript. Any additional information can be made freely available to any scientist on reasonable request.
PB and AE-A designed the study, performed the experiments, and analyzed data and co‐wrote the manuscript. JR and LJ performed the IQS019 sensitivity assays in the B-NHL cell lines. VR designed and performed the animal studies. RP performed the IQS019 synthesis. JT supervised the IQS019 synthesis, interpreted the results, and reviewed the manuscript. JGV, AC-J, AM-C, and AM provided support in the Western blot and flow cytometry analysis and in interpretation of the data. AM helped in designing the immunohistochemical and immunofluorescence assays. EC analyzed clinical data and reviewed the manuscript. AS-B supervised IQS019 kinase inhibition profiling and PK studies. JIB supervised IQS019 synthesis, interpreted the results, and reviewed the manuscript. PP-G analyzed data and co-wrote the manuscript. DC designed the study and reviewed the manuscript. GR conceived and designed the study, analyzed data, and wrote the manuscript. All authors read and approved the final manuscript.
A.S.-B. is an employee of Pangaea Biotech, SL. The remaining authors have no competing financial interests.
Consent for publication
Ethics approval and consent to participate
The manuscript involved the use of human and animal samples. The ethical approvals for this project, including the informed consent of the patients, the animal procedures and the handling of samples, were granted following the guidelines of the Hospital Clínic Ethics Committee (IRB, reg. num. 2012/7498) in compliance with the Animal Ethics Committee of the University of Barcelona (agreement #154/16).
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Figure S1. IQS019 tyrosine kinase inhibitory profiling. Tyrosine kinase (TK) and tyrosine kinase-like (TKL) kinome tree was elaborated on the basis of residual in vitro kinase activity upon exposure to 100 nM or 1 μM IQS019, by means of Kinome Render software (http://bcb.med.usherbrooke.ca/kinomerender.php). Figure S2. Sensitivity of CLL primary cases to IQS019 is independent of IGHV mutational status and involves a caspase-dependent cell death process. (a) CLL primary cells, 9 of them with ummutated (UM) and 6 with mutated (M) IGHV gene, were treated with increasing concentrations of IQS019 for 24h. Cell viability was determined by MTT method. Shown are the median values from each CLL group (UM and M), referred to control, untreated cells. (b) IQS019 induces caspase-dependent cell death in MCL (UPN-1) and in FL (DOHH-2) cell lines, as well as in two representative CLL primary cultures. Cells were exposed for 24 hours to 5 μM IQS019, in the presence of absence of the pan-caspase inhibitor Q-VD-OPh (10 μM). Apoptosis was determined by simultaneous cytofluorimetric detection of Annexin-V and caspase-3/7 activity. (c) A set of 6 CLL primary cultures were treated with IQS019 as indicated, followed by Western Blot detection of phospho-histone H3 (p-H3), using β- actin as a loading control. Figure S3. Flow cytometry determination of CXCR4 membrane expression in B-NHL cell lines. Four representative cell lines were stained with a PE-labeled anti-CXCR4 antibody and analyzed on an Attune cytometer. CXCR4-specific signal (black curves) and isotypic control (grey filled curve) are represented. Figure S4. Safety and PK properties of IQS019-2MeSO3H in mice. (a) Twenty SCID mice (10 males and 10 females) received a single intravenous injection of IQS019-2MeSO3H at a 2 mg/kg, 10 mg/kg, or 50 mg/kg dose, or equivalent volume of vehicle, and animal weight was recorded at days 1, 3, 4, 7, 11, 14, 18 and 21 post-treatment. (b) Mean plasma concentration of IQS019-2MeSO3H in ICR mice over the time, after a single p.o. administration of a 25 mg/kg dose of the compound. Figure S5. Comparison of parental and ibrutinib-resistant derived B-NHL cell line. (a) Dose-response of the UPN-1 parental, and UPN-IbruR derived cell line exposed for 72 hours to increasing concentrations of ibrutinib or IQS019. (b) BTK and PLCG2 exon sequencing in UPN-IbruR cells. (c) Western blot detection of the alternative NF-κB pathway component, p52, in UPN-1 and UPN-IbruR cells. β-actin was used as a loading control. (DOC 3279 kb)
About this article
Cite this article
Balsas, P., Esteve-Arenys, A., Roldán, J. et al. Activity of the novel BCR kinase inhibitor IQS019 in preclinical models of B-cell non-Hodgkin lymphoma. J Hematol Oncol 10, 80 (2017) doi:10.1186/s13045-017-0447-6
- Cell migration
- Mouse model